Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New spinout enterprise from Oxford seeks to accelerate evidence based innovation for treatments and services in mental health and dementia.

Image of a monitor with code displayed on the screen.

Cristal Health (established in May 2019) has been developed as a sustainable way to accelerate the UK-CRIS programme. The UK-CRIS network operates a managed service for secure access to one of the world's largest repositories of de-identified patient data relating to mental health and dementia conditions.

 

Cristal Health presents a real opportunity for accelerating and translating new discovery medicine, including prevention and treatment, into better health outcomes for sufferers of mental illness and their familiesMike Denis, CEO, Cristal Health.

 

Mike Denis, CEO, Cristal Health, said,

"I'm honoured to be leading the team in the joint partnership between the NHS and academia working with industry using real world health data. We're able to add value by continually enriching the clinical content available to clinicians, researchers and scientists which will truly deliver many more opportunities to predict, identify, prevent or manage mental health conditions in the UK."

 

 

The spinning out of remarkable new companies like Cristal Health is great news. It brings in investment which allows for exciting initiatives and innovative activity developed in the NHS and Universities to grow more quickly and become sustainable. Everyone benefits and most importantly our patients.Professor John Geddes, Head of Department of Psychiatry, University of Oxford.

The market for real world evidence and data is projected to grow as organisations seek to reduce costs and time, technology and modelling becomes more widely available and data custodians realise the benefits of facilitating secure access to de-identified data.

Cristal Health will focus on three areas:

• developing offerings to help in early stage drug discovery, reduce clinical trial costs by 12-30%, support post launch and Phase IV evaluation (i.e. following approval) and pharmacovigilance (safety monitoring)

• supporting NHS Trusts in generating revenue from increased participation in the global trials market and developing tools that support service reviews through ongoing monitoring

• and supporting academic research by developing tools to support text-mining to create real knowledge from distributed and heterogeneous data.

Cristal Health will use any profits generated to re-invest into its core purpose of accelerating improvements in medical research, services and outcomes for patients with a mental illness and/or dementia.

To find out more about Cristal Health contact: CEO, Mike Denis, Mike@cristalhealth.co.uk or CIO David, Newton, David@cristalhealth.co.uk.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Tackling Suicide Risk in People With Mental Disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Alcohol affects the Human Biological Clock

The short-term effects of excessive drinking are well known, but to date it has been less certain whether alcohol also accelerates the aging process.

New Meta-Analysis Highlights No Antidepressant Effect of Statins Administered in Monotherapy

This new systematic review and meta-analysis of randomised controlled trials assesses the effects of statins given alone, without concomitant antidepressant treatment, in people with depressive symptoms, but who do not have a formal diagnosis of a depressive disorder.

New Oxford Study Evaluates Pharmacological Treatment for Insomnia

Two drugs, eszopiclone and lemborexant – both not currently licenced for the treatment of insomnia in the UK – were shown to perform better than others, both in the acute and long-term treatment of insomnia in adults, according to a new Oxford study exploring the pharmacological management of insomnia.

Moderate Drinking Linked to Brain Iron and Cognitive Decline

Consumption of seven or more units of alcohol per week is associated with higher iron levels in the brain. Iron accumulation in the brain has been linked with Alzheimer's and Parkinson's diseases and is a potential mechanism for alcohol-related cognitive decline.